EDISON, N.J., May 29, 2018 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the development and commercialization of therapeutic drugs for the treatment of hepatitis B virus (HBV) announced today, that it will present at the 2018 Biotechnology Innovation Organization (BIO) International Convention being held June 4-7, 2018 in Boston, Massachusetts.
James Sapirstein, Chief Executive Officer of ContraVir, will provide an update on the company’s business during a live presentation and will be available to meet with investors and other companies registered to attend the conference. Interested parties may contact ContraVir through the BIO One-on-One Partnering™ System.
| Event: | 2018 BIO International Convention |
| Date: | Tuesday, June 5, 2018 |
| Time: | 3:00PM ET |
| Location: | Theater 3 |
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). The company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™, a nucleoside analog lipid prodrug of tenofovir (TFV), is designed to deliver higher hepatic intracellular concentrations of the active tenofovir species (tenofovir diphosphate) while reducing concentrations of tenofovir outside the liver, causing less off-target toxicities and side-effects. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a novel structure that increases its potency and selective index against HBV. In vitro and in vivo studies have thus far demonstrated that CRV431 reduces HBV DNA and other viral proteins, including surface antigen (HBsAg). For more information visit www.contravir.com
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028